~~<i id='50D32F5D30'><strike id='50D32F5D30'><tt id='50D32F5D30'><pre id='50D32F5D30'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：fashion 2025-10-02 04:53:32 Page View：419

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Has Bernie Sanders reached the limit of his pharma bullying effort?
Next article： Psychedelics group wrestles with new pharma identity

comprehensive

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

White House finalizes ITC's import ban of latest Apple Watches

AnimportbanofcertainAppleWatchesofficiallygoesintoeffectonTuesday.JustinSullivan/GettyImagesAnimport

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

InhonorofJPMWeek,you’rereadingaspecialeditionofourbiotechnewsletter,TheReadout.Tostayontopofthelates